

VALBIOTIS obtains the European patent for VALEDIA®


- **Guaranteed exclusivity on the prediabetes and metabolic diseases market in 38 countries across Europe, including the European Union.**
- **VALEDIA® now holds industrial property rights for the two major global markets: Europe and the United States.**
- **An important milestone for establishing a commercial partnership with a major player in the healthcare sector.**

La Rochelle, February 11, 2019 (5:40 pm CET) – **VALBIOTIS** (FR0013254851 - ALVAL / eligible PEA/SME), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, **announces the obtention of the European patent for TOTUM-63¹. This patent directly covers the active substance of VALEDIA® for use in 38 European countries on the prediabetes and metabolic diseases market, including type 2 diabetes and NAFLD.** After obtaining the US patent in 2018, VALBIOTIS' industrial property for VALEDIA® is now protected on its two main global markets (Europe and the United States). These markets have similar-sized prediabetic populations, each of which exceeds 80 million people^{2,3}.



 *This European recognition of VALEDIA® is a significant milestone in accessing the prediabetes market in Europe. After obtaining the patent in the United States last year, VALBIOTIS now has guaranteed exclusivity for VALEDIA® on the two major global prediabetes markets, on both sides of the Atlantic. This will be a crucial asset for securing future partnerships with players in the healthcare sector; it paves the way for an expected commercial success for VALEDIA®. Furthermore, this favorable decision validates our expertise in terms of developing innovative and patentable plant-based active substance, for preventing and combating metabolic diseases*.*

Sébastien PELTIER
CEO of VALBIOTIS



1. «A composition comprising a mixture of plant extracts, or a mixture of the molecules contained in these plants, used to target carbohydrate and/or lipid metabolism», application no.: EP 15801895.2.
2. Eades C. et al., Prevalence of impaired glucose regulation in Europe: a meta-analysis, The European Journal of Public Health, Vol. 26, No. 4, 699-706, 2016.
3. Center for Disease Control and Prevention, July 2018, www.cdc.gov/features/prediabetes-awareness-campaign/index.html

This patent, obtained in less than 3 years, guarantees exclusive exploitation rights of VALEDIA® until 2035 in Europe, including the 28 countries of the European Union. In line with the American patent that had already been obtained, this patent grants protection over extensive claims, in particular, the exact composition of the active substance (plant extracts and biomolecules), the possible combinations with other products or substances, and most importantly, the specific application of this innovation in the field of metabolic diseases.

The TOTUM-63 patent is co-owned with the CNRS (French National Center for Scientific Research), Clermont Auvergne University and La Rochelle University, long-standing academic partners of VALBIOTIS since its creation in 2014. The strategic plan is to register the patent globally in more than 60 countries, including European and North American territories. It has already been granted and registered in France, the United States, and South Africa.

About TOTUM-63, the main active ingredient of VALEDIA®

TOTUM-63 is based on a specific and patented combination of 5 plant extracts selected for their effects on the metabolism. It acts on various pathophysiological targets of type 2 diabetes to reduce the clinical risk factors of the disease.

This first-in-class product has been developed to introduce a new perspective into prediabetes management and to help pre-diabetic people live healthy lives.

ABOUT VALBIOTIS

VALBIOTIS is a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the healthcare sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases. VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including the La Rochelle University, the CNRS and the Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The company is located at 3 sites in France - Périgny, La Rochelle (17) and Riom (63) - in addition to an American office in Boston (MA).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF).

VALBIOTIS is PEA/SME eligible.

Find out more about VALBIOTIS:

www.valbiotis.com



Name: VALBIOTIS - ISIN Code: FR0013254851 - Mnemonic code: ALVAL



C
O
N
T
A
C
T
S

FRANCE.

CORPORATE COMMUNICATION I VALBIOTIS

Carole ROCHER / Marc DELAUNAY

+33 5 46 28 62 58 | carole.rocher@valbiotis.com / marc.delaunay@valbiotis.com

FINANCIAL COMMUNICATION I ACTIFIN

Stéphane RUIZ

+33 1 56 88 11 14 | sruiz@actifin.fr

MEDIA RELATIONS I MADIS PHILEO

Guillaume DE CHAMISSO

+ 33 6 85 91 32 56 | guillaume.dechamisso@madisphileo.com

UNITED STATES.

SOLEBURY TROUT

Rebecca JOHN / Patrick TILL

+1.646.378.2935 | rjohn@troutgroup.com / ptill@troutgroup.com

Disclaimer

This press release contains forward-looking statements concerning the objectives of VALBIOTIS. VALBIOTIS considers that these projections are based on information currently available by VALBIOTIS and on reasonable assumptions.

However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of VALBIOTIS filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number I.17-012 on April 5, 2017 as well as in its 2017 annual financial report filed with the French Financial Markets Authority on April 3, 2018. These documents are available on the Company's website (www.valbiotis.com).

VALBIOTIS declines all responsibility for updating or revising these forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, VALBIOTIS shares in any country.